الفهرس 
MANAGEMENT OF BENIGN PROSTATE HYPERPLASIAOnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
More than 50% of men over 50 are affected with Benign Prostatic Hyperplasia (BPH) and more than 35% of them are symptomatic with Lower Urinary Tract Symptoms (LUTS).
Since 1950s, the gold standard surgery for symptomatic cases of benign prostatic hyperplasia (BPH) has been monopolar transurethral resection of the prostate (TURP).
Many minimal invasive technologies have emerged in the last twenty years, diode laser vaporization of prostate or bipolar vaporization of prostate are becoming a new standard.
Bipolar TURP permits treatment while irrigation with isotonic normal saline (NaCl 0.9%) not glycine which provides better visualization and less disturbances in electrolytes preventing TUR syndrome.
Bipolar Transurethral vaporization of the prostate (B-TUVP) has better hemostasis outcome which made it suitable for those who have any bleeding tendency achieving less intraoperative and post operative bleeding which leads to shorter catheterization time and same day discharge.
Laser devices have also conquered the practice of prostate resection specially in high-risk patient that had bleeding tendency or on anticoagulation drugs, in the last few years, the main laser techniques currently used are LBO (lithium Borat), Diode lasers, Holmium yttrium-aluminum-gamete laser (Ho: YAG) and Thulium YAG (Tm-YAG).
All these laser techniques can perform transurethral vaporization or enucleation and can be performed using isotonic normal saline as an irrigation fluid which reduces the risk of TUR syndrome. Also, they have a very good hemostasis profile which made them suitable for patients on anticoagulants treatment.
The primary challenge with diode lasers is deep tissue penetration and coagulative necrosis this is associated with dysuria, passage of sloughed tissue, and higher reoperation rates for bladder neck stenosis.